Improvement of psoriasis during sunitinib therapy for renal cell carcinoma

Am J Med Sci. 2010 Jun;339(6):580-1. doi: 10.1097/MAJ.0b013e3181dd1aa5.


Sunitinib is an oral tyrosine kinase inhibitor, which is indicated for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. The authors report the case of a patient who underwent treatment for renal cell carcinoma and noted additional benefit by improvement in his psoriatic skin lesions. This may be attributed to the antiangiogenic activity of sunitinib by inhibition of vascular endothelial growth factor receptors.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / complications
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Humans
  • Indoles / therapeutic use*
  • Kidney Neoplasms / complications
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Male
  • Middle Aged
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Pyrroles / therapeutic use*
  • Sunitinib


  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib